Parkinson’s drug development halted after midstage trial failure
Drugmakers Biogen and Denali Therapeutics said they will discontinue development of BIIB122 for idiopathic Parkinson’s disease after the drug failed to meet primary and secondary endpoints in a phase 2b study. The phase 2b Luma study evaluated BIIB122, an investigational LRRK2 inhibitor, in 648 people with early stage Parkinson’s disease between the ages of 30 […] The post Parkinson’s drug development halted after midstage trial failure appeared first on Becker's Hospital Review | Hea...
Original Source
Read the full article at Beckershospitalreview →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.